Selecting Between Adalimumab Biosimilars for Your Patients

EP: 1.The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

EP: 2.An Overview of Adalimumab Biosimilars

EP: 3.The Pharmacological Aspects of Adalimumab Biosimilars

EP: 4.The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases

EP: 5.Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings

EP: 6.The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars

EP: 7.Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

Now Viewing

EP: 8.Selecting Between Adalimumab Biosimilars for Your Patients

EP: 9.Switching From Adalimumab to a Biosimilar

EP: 10.Clinical Experience With Initiating Adalimumab Biosimilars

EP: 11.The Role of Health Care Providers on Encouraging Adalimumab Biosimilar Use

EP: 12.Copay Assistance Programs for Adalimumab Biosimilars

EP: 13.Common Questions From Patients About Adalimumab Biosimilars

EP: 14.The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars

EP: 15.Resources for Patients and Providers on Adalimumab Biosimilars

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The discussion revolves around how to choose the appropriate biosimilar for patients. In dermatology, options are limited, especially for conditions like psoriasis where newer treatments may outperform existing biosimilars. However, for conditions like hidradenitis, where choices are scarce, biosimilars offer a straightforward solution. The growth of biosimilars is anticipated to provide more options for clinicians, allowing them to select treatments based on efficacy and patient insurance coverage.

Clinicians often consider insurance formularies to anticipate the most easily approved biosimilar for each patient. In conditions like inflammatory bowel disease (IBD), certain biologics like Adalimumab play a significant role in treatment, leading to the proliferation of biosimilars. While payer preferences often influence prescribing decisions, clinicians prioritize factors like citrate-free formulations, small volume, high concentration, and robust patient support programs when choosing biosimilars, aiming for broader uptake and patient adherence.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.